2015-08-04 21:45:53 UTC

Report: New Acid Blocker Holds its Own Against PPIs

Aug. 4, 2015

The study suggests that the novel drug has a similar safety profile as PPIs, which are widely used in treating peptic ulcer recurrence.

GI & Hepatology News reports that the new acid blocker vonoprazan, which is currently only approved in Japan, has been effective at suppressing peptic ulcer recurrence during NSAID therapy. The drug is part of "a new class of acid-suppressing drugs called potassium-competitive acid blockers, which, unlike Proton Pump Inhibitors (PPIs), do not need to be activated by acid to become effective and are not affected by genetic variations," according to the article. 

The study, which was supported by Takeda Pharmaceuticals International, suggests that the drug has a similar safety profile as PPIs, which are widely used in treating peptic ulcer recurrence. 

A consultant for the study, Yuji Mizokami, MD, pointed out that after two years of follow-up "rates of recurrent peptic ulcers or hemorrhagic lesions in the stomach or duodenum among patients who took vonoprazan (marketed in Japan as Takecab) at a 10-mg or 20-mg daily oral dose were numerically but not statistically significantly lower than those for patients who took a 15-mg once daily dose of lansoprazole (Prevacid)," according the GI & Hep News.

Dr. Mizokami presented these findings at Digestive Disease Week® 2015. 

Find out more about the study at GI & Hep News.


More on Gastric Acid Secretion

2017-18 AGA GI Resource Catalog

May 30, 2017

Whether it’s the latest in clinical education, cutting-edge science or navigating the future of medicine, AGA has you covered. Find resources to address all of your professional needs in the GI Resource Catalog.

DDSEP 8 - Complete

April 12, 2016

The eighth edition of AGA's premier GI education program features new and expanded content to help you enhance your knowledge, build expertise and improve patient care.

AGA DHRP Now Open to Report on Hepatitis C and IBD Data

Oct. 17, 2013

The AGA Digestive Health Recognition Programâ„¢ (DHRP) is now open to report on 2013 hepatitis C and IBD data. The DHRP was developed by AGA to make it easy for clinicians to demonstrate quality, achieve recognition, qualify for payor incentives, avoid CMS penalties and earn ABIM MOC points.